How many paraquat lawsuits have been filed in 2026?

Over 6,400 paraquat-Parkinson's disease lawsuits are pending in federal MDL-3004, with approximately 8,000 total cases including state courts. Syngenta settled the first bellwether trial in January 2026 one day before it was set to begin.

What is the connection between paraquat and Parkinson's disease?

A 2019 meta-analysis of 13 studies found that paraquat exposure increased Parkinson's disease risk by 64%. One study found exposed individuals were more than twice as likely to develop the disease. Paraquat is banned in over 60 countries but still used in the U.S.

What medical records are needed for paraquat lawsuits?

Paraquat cases require Parkinson's disease diagnosis records from neurologists, occupational exposure documentation, employment or farm records proving proximity to paraquat application, and medical history spanning decades due to the long latency period between exposure and diagnosis.

Paraquat Lawsuits 2026: Syngenta Settles First Trial as 6,400 Federal Cases Mount

Syngenta settled the first U.S. paraquat-Parkinson's disease trial one day before trial proceedings were scheduled to begin in January 2026 in Philadelphia. The plaintiff, Bill Mertens, is a 77-year-old retired landscaper who was exposed to paraquat during the 1980s and 1990s and received a Parkinson's disease diagnosis in 2021. More than 6,400 federal cases remain pending in MDL-3004, representing the eighth-largest active multidistrict litigation in the federal system.

The Mertens resolution marked the second instance in six months in which Syngenta resolved a paraquat claim on the eve of trial. The manufacturer has consistently avoided taking a paraquat-Parkinson's claim through a full jury verdict, including an earlier $187 million multi-plaintiff settlement in 2021.

6,400+

Federal paraquat-Parkinson's lawsuits pending in MDL-3004 (AboutLawsuits)

64%

Increased Parkinson's risk from paraquat exposure, per 2019 meta-analysis

60+

Countries that have banned paraquat, including the EU, China, and Canada

Scientific Evidence and Regulatory Status

Epidemiological research connecting paraquat exposure to Parkinson's disease spans over a decade. A 2019 meta-analysis of 13 epidemiological studies found that occupational paraquat exposure increased the risk of developing Parkinson's disease by 64%. Specific studies within that body of literature identified exposure odds ratios exceeding 2.0 compared to unexposed cohorts.

The Michael J. Fox Foundation has submitted multiple peer-reviewed studies to the EPA detailing how paraquat creates oxidative stress that damages dopaminergic neurons. While the EPA's 2024 interim registration review evaluated conflicting data from an updated Agricultural Health Study cohort, regulatory pressure continues to build.

Paraquat remains widely used in commercial agriculture, with over 10 million pounds applied annually in the United States. It has been banned across more than 60 countries, including the European Union, China, and Canada.

Important

EPA Regulatory Review Announced January 2026

EPA Administrator Lee Zeldin announced in January 2026 that paraquat registrants must submit additional real-world exposure data. The administrative review could affect evidentiary baselines for both pending and future exposure claims.

MDL Centralization and Settlement Posture

MDL-3004 is centralized before Judge Nancy J. Rosenstengel in the Southern District of Illinois. When combined with state court dockets in Pennsylvania, California, and Illinois, the active caseload totals approximately 8,000 filed claims.

A tentative global settlement framework was discussed in April 2025, but has not yet been finalized. The district court has managed discovery deadlines while settlement negotiations proceed, requiring counsel to maintain verified medical files for potential trial remand tracks.

Traditional Approach vs LlamaLab Solution

Traditional Approach

Decade-Long Care Gaps
Exposure dating back to the 1980s with records scattered across closed rural clinics
Fragmented Neurology Charts
Movement disorder notes, DAT-scans, and medication titration logs separated across health systems
Manual Request Tracking
Weeks spent calling legacy custodians and state licensing boards to locate archived records
Hidden & Unpredictable Costs
Per-page fees, rush charges, and surprise bills that blow up your budget

LlamaLab Solution

Reverse Provider Search
Uses insurance data to fill in treatment gaps clients don't always remember, surfacing facilities, dates, and clinicians as needed
4-Day Average Turnaround
Complete medical records returned in 4 days on average, with roughly 30-40% returned same-day on electronic requests
Disbursement Flow-Through
Itemized per-case invoice that flows through as a recoverable case disbursement on settlement statements
Flat Transparent, Risk-free Pricing
1 flat fee covers all costs. Only pay full price for cases that authorize

Medical Record Retrieval for Multi-Decade Dockets

Paraquat litigation involves substantial latency intervals: the period between initial chemical exposure and neurological diagnosis frequently spans 10 to 30 years. An agricultural applicator exposed in 1985 may not have exhibited motor symptoms until 2015.

Establishing a complete claim file requires:

Neurological evaluation notes documenting progressive motor symptoms (resting tremor, rigidity, bradykinesia, postural instability).
Response logs to dopaminergic therapy (e.g., levodopa/carbidopa).
Occupational exposure records, commercial applicator licenses, and farm employment documentation.
Longitudinal primary care records ruling out secondary parkinsonism etiologies.

Because Parkinson's disease diagnosis is clinical: there is no single biomarker or blood test, the medical file must establish a consistent clinical progression documented by treating neurologists.

Reverse search uses insurance data to fill in treatment gaps clients don't always remember, surfacing facilities, dates, and clinicians as needed.

Strategic Priorities for 2026

Key Points

Essential takeaways from this article

Monitor EPA re-evaluation proceedings for findings that impact general causation disclosures.

Prepare dual-track inventory management: ensure files meet proposed settlement criteria while remaining trial-ready if talks stall.

Track state legislative restrictions in agricultural jurisdictions including Pennsylvania, Missouri, and Vermont.

Retrieve complete multi-decade medical histories from neurology practices, rural health clinics, and occupational providers.

Evidentiary Priorities for Paraquat Dockets

The paraquat litigation continues to progress through settlement negotiations and trial scheduling. Syngenta's pre-trial settlement pattern highlights the practical value of verified clinical documentation and detailed exposure timelines.

Securing complete neurological records, diagnostic studies, and treatment histories ensures that claimant files are positioned for resolution under any resulting settlement framework.

Medical record retrieval functions as a direct case expense, with itemized per-case invoices flowing through to settlement statements upon resolution.

Build Verified Paraquat Case Files

Retrieve complete multi-decade medical histories from neurologists and regional clinics in 4 days on average. Verify Parkinson's diagnoses and exposure timelines at scale.

Start Retrieval See How It Works

Sources: The New Lede, Drugwatch, AboutLawsuits, AboutLawsuits MDL Updates, EWG, EPA, Drugwatch EPA Review.